353 related articles for article (PubMed ID: 29275525)
1. A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer.
Schiodt M; Vadhan-Raj S; Chambers MS; Nicolatou-Galitis O; Politis C; Coropciuc R; Fedele S; Jandial D; Zhang J; Ma H; Saunders DP
Support Care Cancer; 2018 Jun; 26(6):1905-1915. PubMed ID: 29275525
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.
Ehrenstein V; Heide-Jørgensen U; Schiødt M; Akre O; Herlofson BB; Hansen S; Larsson Wexell C; Nørholt SE; Tretli S; Kjellman A; Glennane A; Lowe KA; Sørensen HT
Cancer; 2021 Nov; 127(21):4050-4058. PubMed ID: 34310704
[TBL] [Abstract][Full Text] [Related]
3. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
Saad F; Brown JE; Van Poznak C; Ibrahim T; Stemmer SM; Stopeck AT; Diel IJ; Takahashi S; Shore N; Henry DH; Barrios CH; Facon T; Senecal F; Fizazi K; Zhou L; Daniels A; Carrière P; Dansey R
Ann Oncol; 2012 May; 23(5):1341-1347. PubMed ID: 21986094
[TBL] [Abstract][Full Text] [Related]
4. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
5. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
7. Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis.
Zhang C; Shen G; Li H; Xin Y; Shi M; Zheng Y; Wang M; Liu Z; Zhao Y; Zhao F; Ren D; Zhao J
Spec Care Dentist; 2024; 44(2):530-541. PubMed ID: 37219080
[TBL] [Abstract][Full Text] [Related]
8. Influence of prostate cancer status on the prevalence of medication-related osteonecrosis of the jaw.
Yasui T; Kimura M; Nagamine H; Yajima S; Karube T; Sato H; Asoda S; Hara S; Onizawa K
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Mar; 131(3):312-318. PubMed ID: 33431343
[TBL] [Abstract][Full Text] [Related]
9. Antiresorptive treatment-associated ONJ.
Eleutherakis-Papaiakovou E; Bamias A
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 29063702
[TBL] [Abstract][Full Text] [Related]
10. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
11. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.
Everts-Graber J; Lehmann D; Burkard JP; Schaller B; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
J Bone Miner Res; 2022 Feb; 37(2):340-348. PubMed ID: 34787342
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
13. Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark.
Corraini P; Heide-Jørgensen U; Schiødt M; Nørholt SE; Acquavella J; Sørensen HT; Ehrenstein V
Cancer Med; 2017 Oct; 6(10):2271-2277. PubMed ID: 28941210
[TBL] [Abstract][Full Text] [Related]
14. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.
Liu FC; Luk KC; Chen YC
Osteoporos Int; 2023 Oct; 34(10):1729-1737. PubMed ID: 37326685
[TBL] [Abstract][Full Text] [Related]
15. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
[TBL] [Abstract][Full Text] [Related]
16. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
[TBL] [Abstract][Full Text] [Related]
17. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
18. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
[TBL] [Abstract][Full Text] [Related]
19. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
Sidhu HK
Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
[TBL] [Abstract][Full Text] [Related]
20. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
